Glenveigh Pharmaceuticals

Glenveigh Medical, formerly known as Glenveigh Pharmaceuticals, is a life science company specializing in the development of therapeutics and medical devices for obstetrics and maternal-fetal medicine. Based in Chattanooga, Tennessee, the company was founded in 2004 by Dr. C. David Adair to address critical unmet needs in pregnancy-related conditions. Its primary pharmaceutical asset is digoxin immune fab (DIF), an ovine polyclonal antibody fragment that targets endogenous digitalis-like factors to treat severe preeclampsia and eclampsia. Glenveigh also developed a suite of medical devices, including the Ebb postpartum hemorrhage tamponade and the Jetty system for vaginal laceration repair. The company has successfully navigated the regulatory landscape, securing FDA Orphan Drug and Fast Track designations for its lead drug candidate and obtaining clearances for its device portfolio.